echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Chengdu Meikekang completed nearly 100 million yuan pre-A round of financing

    Chengdu Meikekang completed nearly 100 million yuan pre-A round of financing

    • Last Update: 2021-02-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 16, Chengdu McCorcon Biotech Co., Ltd. (McCorcon Bio) announced the completion of nearly 100 million yuan of pre-A round of financing, which was funded exclusively by KIP Capital (Korea Investment Partners), the proceeds of which were mainly used to promote the progression of McCorcon Bio's geriatric shingles vaccine pipeline and the new wheeled virus vaccine pipeline into clinical trials.Previously, McCormant Bio completed an tens of millions of yuan angel round of financing in 2017.
    founded in 2016,
    McCorcon Bio is a new vaccine industrialization company founded by Dr. Chen Dexiang, with the country's first new adulation platform, recombinant protein platform and a number of clinically declared vaccine projects, including therapeutic vaccines for major infectious diseases, allergic diseases and cancers.

    At present, McCorcon Bio has more than 10 international cutting-edge technology and more than 20 invention patents, and has laid out three core vaccine pipelines and three reserve vaccine pipelines, covering hepatitis B, cancer and other fields, and the two fastest-growing pipelines are the two projects mainly used to advance the financing: the new geriatric shingles vaccine and the new wheeled virus vaccine, respectively, have completed the preclinical process development and evaluation, the company is expected to complete the IND declaration by the end of this year.

    And as a vaccine research and development company, in this new crown outbreak, McCorcon Bio also actively contributed to its own strength, Dr. Chen Dexiang told Arterial Network, McCorcon Bio with its own expertise to develop the new crown vaccine-related admones, and has been in two countries-supported new crown vaccine projects to launch a trial evaluation. "Through existing animal experiments, it can be seen that the new crown vaccine, aided by adsulation, can significantly enhance the immunogenicity of the vaccine, and increase production and reduce the original dosage. We have started the layout of pilot production, and is designing the decoration workshop, hope to be able to complete large-scale production by the end of the year, operation. Dr

    , founder of McCormant Bio, laughs that this can't be separated from the support of the team and the company's technological leadership.

    to investing in McCormigon Bio, KIP Capital Investment Vice President Fu Hao said: "China's vaccine industry and foreign countries have a large technical gap, product technology is old, industry security incidents are emerging." It is gratifying to note that we have also recently seen excellent start-up teams that are innovating and trying to change this situation, and McCorcon is one of us who is very optimistic. At present, KIP Capital has always maintained a steady pace of investment, and is proud to work with McCormughon Bio to drive the Chinese vaccine industry to catch up and surpass.The first innovative shingles vaccine and rota virus vaccine in China is expected to complete THED declaration

    herpes is a herpes-like skin disease that appears in groups of blisters on the skin and is accompanied by tingling. The diseased population is mostly elderly, after the treatment is still left with a longer period of skin tingling, also known as shingles after the nerve pain. According to the "Old Age Prevention and Control" statistics, about 80% of the elderly have symptoms of shingles after the nerve pain.

    the first generation of shingles virus vaccine is only 50% effective on average among people over 50 years of age, and injections for people over 80 years of age are almost ineffective. A new vaccine for herpes in old age for Mekocon organisms is expected to fill this gap. With the help of advents, The new shingles vaccine of McCorcon Bio can effectively improve the effectiveness of treatment by 20% to 30%, so that people over 50 years of age can achieve more than 90% effectiveness of vaccination, so that people over 80 years of age can also benefit from the new vaccine.

    diarrhoea is the second leading cause of death among children under five years of age, with about 525,000 children under the age of five dying each year from diarrhoeal diseases, according to the World Health Organization (WHO). The rotovirus is one of the main pathogens that cause diarrhea in infants and young children, mainly infecting children's small intestine skin cells, causing diarrhea, almost every five-year-old child in the world has been infected with the rotovirus at least once.

    the traditional first-generation rovirus vaccine is given oral, the disadvantage of this method of drug treatment is that it may trigger a serious side effect of the child's intestines, the proportion of about one in 100,000, and its efficacy is debatable. The new rotavirus vaccine currently being developed by McCorcon Bio uses a new injection method for child giving, which can improve the effectiveness of the vaccine while mitigating side effects.

    senior experts, the return team has a wealth of experience in vaccine industrialization

    , Dr. Chen Dexiang, Ph.D. in Immunology/Microbiology, Mississippi State University, usa, completed his postdoctoral research at the University of Alabama (Birmingham). Dr. Chen has served as project manager for Pfizer Vaccines in the United States, director of research and development at Novartis Vaccines in the United States, and technical director of vaccine technology at PATH in the United States.

    In his nearly 30 years of research, development and promotion of vaccines, Dr. Chen dexiang has mastered the international cutting-edge vaccine and ad technology, has extensive industrialization experience, and has participated in and led the development of more than 20 infectious diseases and therapeutic vaccines, including the available pneumonia vaccine, brain vaccine, roulent virus vaccine and influenza vaccine.

    It's worth noting that during his time at PowderJect, Dr. Chen founded and led a vaccine program that received $80 million in equity financing and helped the company grow into the world's sixth-largest vaccine producer in just a few years in early 2000.

    team members of McCormenko Bio also have extensive experience in vaccine industrialization. Dr. He Yonggang, Vice President of Production, graduated from newcastle University in the United Kingdom and completed his postdoctoral research at the University of Newcastle in the United Kingdom. Dr. He Yonggang has been engaged in adjunging-related technical research and vaccine research and development for 15 years and has served as Project Technical Officer of the China Office of the World Health Science and Technology Organization (PATH) in the United States, managing the implementation and implementation of several vaccine projects in China.

    McCorcon Vice President of Biodevestry, Lichun Dong graduated from Mississippi State University and has been involved in vaccine development for 27 years at the University of Alabama At the University of Alabama, Birmingham School of Medicine, the University of Rochester, and the University of Washington.

    about KIP capital KIP Capital is Asia's leading investment institution, founded in 1986, with a cumulative capital management of more than US$5 billion, and has set up seven RMB funds in China. KIP focuses on the development of a number of emerging areas, especially biomedicine/big health, big consumption/Internet of Things, high-tech/AI, and more than 200 companies have been listed on the secondary market in various countries.
    as an organization with a global distribution in the global health industry, KIP Capital has invested in a number of domestic star projects in vertical areas such as biomedicine, medical devices and health services, such as the innovative biopharmaceutical company Fuhong Hanxuan (2696. HK), the original innovative pharmaceutical research and development enterprise Yasheng Pharmaceuticals (6855. HK), interventional device supplier Peijia Medical, respiratory field innovative biopharmaceuticalAnsun Biopharma, online pharmacy platform Quanyuantang, etc. (Arterial mesh)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.